Source-grounded facts extracted from Immuneering Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Immuneering Corp reported the first quarter ended March 31, 2024 results: net income Net loss attributable to common stockholders was $14.3 million, or $0.49 per share, EPS $0.49 per share.
“Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2024”
Thomas J. Schall, Ph.D. was appointed as Director at Immuneering Corp.
“On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.”
Immuneering Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
“today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business updates.”
Immuneering Corp: Amended and restated bylaws to address universal proxy rules, enhance stockholder nomination and proposal procedures, and require white proxy card for stockholder solicitations (effective 2024-02-01).
“On February 1, 2024, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.